hematologic malignancies after umbilical cord blood transplantation
Conditions
Interventions
Probiotics Treatment Group:From pretreatment to 30d daily intake of a quantitative probiotics components, adults 2 times a day, 10g
children 2 times a day, once 5g, 40 degree C, the following warm boiling water blunt (taboo and antibiotics taken at the same time)
Blank control Group:No Probiotics component
Sponsors
Anhui Provincial Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clearly diagnosed patients with malignant hematological diseases any weight, age, and race; 2. Patients and their families voluntarily carry out unrelated umbilical blood transplantation (UCBT) and sign informed consent; 3. Patients and their families volunteered to participate in this study and sign informed consent; 4. Each participant must sign an informed consent (ICF) to indicate that he/she understands the purpose and procedure of the study and is willing to participate in the study; from the patient's condition, if the patient's signature is not conducive to the treatment of the illness, the legal representative will sign ICF.
Exclusion criteria
Exclusion criteria: 1. Patients with serious disorders of organ dysfunction or disease, such as heart, liver, kidney and pancreas, and other serious diseases and dysfunction; 2. Those who cannot tolerate oral probiotics components; 3. Participants and/or authorized family members refused to UCBT and probiotic components; 4. Three months to participate in other similar clinical studies; 5. The researchers found that the group was not suitable (for example, patients who were expected to be unable to adhere to the treatment due to funding problems).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of severe acute graft-versus-host disease (aGVHD); | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of pre-engraftment syndrome;The incidence and time of neutrophil implantation;The incidence and time of platelet implantation;Immune function reconstruction;The incidence of infection;180d transplant related mortality;Sequencing of fecal bacteria group; | — |
Countries
China
Contacts
Public ContactHui-Lan Liu
Department of Hematology, Anhui Provincial Hospital, Anhui Provincial Hospital
Outcome results
None listed